Adcentrx Therapeutics Reports the US FDA’s IND Clearance of ADRX-0405 to Treat Advanced Solid Tumors
Shots:
- Adcentrx’s IND application for ADRX-0405 has been approved by the US FDA to begin its human evaluations for treating advanced solid tumors
- The FIH dose escalation & expansion P-Ia/b trial will assess safety, tolerability & optimal dose of ADRX-0405 among patients with advanced solid tumors, incl. mCRPC, with first patient recruitment planned in Q4’24 & initial findings in Q4’25
- ADRX-0405 is a next-gen. ADC developed using i-Conjugation technology, comprising of humanized IgG1 Ab & targets STEAP1 protein which is upregulated in prostate & certain other cancers. It has depicted favorable PK profile, safety & efficacy across multiple tumor models
Ref: Adcentrx | Image: Adcentrx
Related News:- Novartis’ Kisqali (Ribociclib) Gains the CHMP’s Positive Opinion as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer (EBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
